Current and Emerging Treatments in the Management of Castration-Resistant Prostate Cancer

David Shapiro; Basir Tareen


Expert Rev Anticancer Ther. 2012;12(7):951-964. 

In This Article

Expert Commentary

We believe that the field of prostate cancer has made tremendous strides in treating CRPC. As data from ongoing trials mature over this and next year, we expect to see a whole host of new options for this late-stage malignancy. It appears that drugs like MDV3100 and radium-223 have the potential to join cabazitaxel in becoming second-line treatments after docetaxel-based chemotherapy failure in CRPC patients. We also believe that agents like sipuleucel-T may be used significantly earlier in the disease process.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.